The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
Myra Hardy, Josaia Samuela, Mike Kama, Meciusela Tuicakau, Lucia Romani, Margot J Whitfeld, Christopher L King, Gary J Weil, Anneke C Grobler, Leanne J Robinson, John M Kaldor, Andrew C Steer
PLoS Neglected Tropical Diseases | PUBLIC LIBRARY SCIENCE | Published : 2020
Lymphatic filariasis has remained endemic in Fiji despite repeated mass drug administration using the well-established and safe combination of diethylcarbamazine and albendazole (DA) since 2002. In certain settings the addition of ivermectin to this combination (IDA) remains a safe strategy and is more efficacious. However, the safety has yet to be described in scabies and soil-transmitted helminth endemic settings like Fiji. Villages of Rotuma and Gau islands were randomised to either DA or IDA. Residents received weight-based treatment unblinded with standard exclusions. Participants were actively found and asked by a nurse about their health daily for the first two days and then asked to ..View full abstract
Awarded by Bill & Melinda Gates Foundation
This study was supported in part by grant OPPGH5342 from the Bill & Melinda Gates Foundation to Washington University. The study was also supported in part by the Coalition for Operational Research on Neglected Tropical Diseases, which is funded at the Task Force for Global Health primarily by the Bill & Melinda Gates Foundation, by the United Kingdom Department for International Development, and by the United States Agency for International Development through its Neglected Tropical Diseases Program. Albendazole (produced and donated by GlaxoSmithKline) and diethylcarbamazine (produced and donated by Eisai Co., Ltd.) were obtained from Ministry of Health stocks in Fiji. Ivermectin was purchased from Merck Sharp Dohme (Australia) Pty. Ltd. and permethrin cream 5% was purchased from Pharmatec Wholesale Company Ltd. Fiji and manufactured by Glenmark Pharmaceuticals Ltd. The funders and drug donors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.